This study aimed to determine the effectiveness of treatment by laser or Intravitreal anti VEGF- Bevacizumab (IVB) or combined therapy (both laser and anti-VEGF) in diabetic macular edema (DME). A prospective observational study in which 90 eyes with diabetic macular edema (DME) were enrolled. According to patient compliance, they were divided in to 3 groups where there was 30 eyes in each group. Patients with DME who were treated with laser were observed (group A). Patients with DME who were treated with Intravitreal Bevacizuamb (IVB) were observed (group B).Patients with DME who were treated with both IVB and Laser were observed (group C). All patients underwent complete ophthalmic examination at baseline and at one and three months after treatment. The outcome measures were changes in Central macular thickness(CMT) and best corrected visual acuity(BCVA). A P value less than 0.05 considered statistically significant. One month after treatment, Group B showed more statistically significant reduction in CMT and improvement in BCVA than group A and group C(P<0.05). Three months after treatment, group C showed more statistically significant reduction in CMT and improvement in BCVA when compared to other two groups(P<0.05). Combined therapy with IVB and laser appeared to be superior to Laser alone or IVB alone in reducing macular thickness and improving visual acuity. Thus combined therapy can be considered as most effective treatment in DME.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.